Drug intelligence / Profile preview

BM330

Development stage: Preclinical
Lead developer: Biomissile Pharmaceuticals
Modality: Cell Therapies

Overview

BM330 is a novel preclinical-stage drug developed by Biomissile. It is classified as an NKT cell therapy and functions as a natural killer T cell modulator, indicating its role in influencing the activity of natural killer T cells within the immune system. The drug is currently being investigated for its potential in cancer treatment.

Beyond the preview

Go deeper on BM330.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM330.

Explore the full profile